FDA commissioner Rob Califf (AP Photo/Jose Luis Magana)
July 22, 2022 01:59 PM EDT
FDA+

Su­per-speedy can­cer drug re­views: FDA un­veils new draft guid­ance to help spon­sors ap­ply

Zachary Brennan

Senior Editor

How does a can­cer drug cross the FDA fin­ish line 3-5 months be­fore its PDU­FA date? That’s where the Re­al-Time On­col­o­gy Re­view comes in. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times